· Published by Health Canada · Official notice
This is duplicated text of a letter from Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
December 15, 2010
Subject: Pfizer Initiates Product Withdrawal of THELIN® (sitaxsentan sodium) Worldwide
Dear Health Care Professional,
Pfizer Canada, in collaboration with Health Canada, is voluntarily withdrawing THELIN® (sitaxsentan sodium) tablets from the Canadian market due to concerns about hepatotoxicity.
Pfizer has completed an extensive assessment of the hepatic safety of THELIN®. Based on a review of available information, including new information on two fatalities associated with hepatic injury (a 2009 post-marketing case in the UK and in a 2010 clinical trial case in a US registration program at a study site in India), Pfizer concluded:
Given the above conclusions, Pfizer has decided to voluntarily withdraw its marketing license in all countries where it has an approved marketing authorization. Additionally, Pfizer has decided to discontinue all clinical development of sitaxsentan, including the U.S. and Japan Phase 3 registration trials.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving THELIN® should be reported to Pfizer Canada or Health Canada at the following addresses:
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Telephone: 1-800-463-6001
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
For medical or pharmaceutical requests please contact Pfizer Canada Inc's Medical Information Department at 1-800-463-6001.
Sincerely,
original signed by
Bernard Prigent, MD, MBA
Vice-President and Medical Director
Pfizer Canada Inc.